Deposition of onco-histone H3.3-G34W leads to DNA repair deficiency and activates cGAS/STING-mediated immune responses.

DNA repair H3.3-G34W cGAS/STING-mediated immune responses radiation

Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
14 Feb 2024
Historique:
revised: 08 01 2024
received: 23 11 2023
accepted: 24 01 2024
medline: 14 2 2024
pubmed: 14 2 2024
entrez: 14 2 2024
Statut: aheadofprint

Résumé

Mutations in histone H3.3-encoding genes causing mutant histone tails are associated with specific cancers such as pediatric glioblastomas (H3.3-G34R/V) and giant cell tumor of the bone (H3.3-G34W). The mechanisms by which these mutations promote malignancy are not completely understood. Here we show that cells expressing H3.3-G34W exhibit DNA double-strand breaks (DSBs) repair defects and increased cellular sensitivity to ionizing radiation (IR). Mechanistically, H3.3-G34W can be deposited to damaged chromatin, but in contrast to wild-type H3.3, does not interact with non-homologous end-joining (NHEJ) key effectors KU70/80 and XRCC4 leading to NHEJ deficiency. Together with defective cell cycle checkpoints reported previously, this DNA repair deficiency in H3.3-G34W cells led to accumulation of micronuclei and cytosolic DNA following IR, which subsequently led to activation of the cyclic GMP-AMP synthase/stimulator of interferon genes (cGAS/STING) pathway, thereby inducing release of immune-stimulatory cytokines. These findings suggest a potential for radiotherapy for tumors expressing H3.3-G34W, which can be further improved by combination with STING agonists to induce immune-mediated therapeutic efficacy.

Identifiants

pubmed: 38353495
doi: 10.1002/ijc.34883
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : 429192355
Organisme : German Cancer Research Center (DKFZ)

Informations de copyright

© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547-560.
Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287-294.
Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179-204.
Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071-1078.
Lieber MR, Wilson TE. SnapShot: nonhomologous DNA end joining (NHEJ). Cell. 2010;142(3):496-e1.
Yan CT, Boboila C, Souza EK, et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature. 2007;449(7161):478-482.
Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010;11(3):196-207.
Rossetto D, Truman AW, Kron SJ, Côté J. Epigenetic modifications in double-strand break DNA damage signaling and repair. Clin Cancer Res. 2010;16(18):4543-4552.
Polo SE, Roche D, Almouzni G. New histone incorporation marks sites of UV repair in human cells. Cell. 2006;127(3):481-493.
Dinant C, Bartek J, Bekker-Jensen S. Histone displacement during nucleotide excision repair. Int J Mol Sci. 2012;13(10):13322-13337.
Kornberg RD. Chromatin structure: a repeating unit of histones and DNA. Science (New York, NY). 1974;184(4139):868-871.
McGhee JD, Felsenfeld G. Nucleosome structure. Annu Rev Biochem. 1980;49:1115-1156.
de Graaf CA, van Steensel B. Chromatin organization: form to function. Curr Opin Genet Dev. 2013;23(2):185-190.
Filipescu D, Müller S, Almouzni G. Histone H3 variants and their chaperones during development and disease: contributing to epigenetic control. Annu Rev Cell Dev Biol. 2014;30:615-646.
Lin CJ, Koh FM, Wong P, Conti M, Ramalho-Santos M. Hira-mediated H3.3 incorporation is required for DNA replication and ribosomal RNA transcription in the mouse zygote. Dev Cell. 2014;30(3):268-279.
Adam S, Polo SE, Almouzni G. Transcription recovery after DNA damage requires chromatin priming by the H3.3 histone chaperone HIRA. Cell. 2013;155(1):94-106.
Frey A, Listovsky T, Guilbaud G, Sarkies P, Sale JE. Histone H3.3 is required to maintain replication fork progression after UV damage. Curr Biol. 2014;24(18):2195-2201.
Luijsterburg MS, de Krijger I, Wiegant WW, et al. PARP1 links CHD2-mediated chromatin expansion and H3.3 deposition to DNA repair by non-homologous end-joining. Mol Cell. 2016;61(4):547-562.
Elbakry A, Juhász S, Mathes A, Löbrich M. DNA repair synthesis and histone deposition partner during homologous recombination. Mol Cell Oncol. 2018;5(5):e1511210.
Lan F, Shi Y. Histone H3.3 and cancer: a potential reader connection. Proc Natl Acad Sci U S A. 2015;112(22):6814-6819.
Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10(5):295-304.
Lutsik P, Baude A, Mancarella D, et al. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone. Nat Commun. 2020;11(1):5414.
Yadav RK, Jablonowski CM, Fernandez AG, et al. Histone H3G34R mutation causes replication stress, homologous recombination defects and genomic instability in S. Pombe. Elife. 2017;6:6.
Fang J, Huang Y, Mao G, et al. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction. Proc Natl Acad Sci U S A. 2018;115(38):9598-9603.
Lowe BR, Yadav RK, Henry RA, et al. Surprising phenotypic diversity of cancer-associated mutations of Gly 34 in the histone H3 tail. Elife. 2021;10:10.
Haase S, Banerjee K, Mujeeb AA, et al. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. J Clin Invest. 2022;132(22):e154229.
Mansour WY, Schumacher S, Rosskopf R, et al. Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks. Nucleic Acids Res. 2008;36(12):4088-4098.
Bakr A, Hey J, Sigismondo G, et al. ID3 promotes homologous recombination via non-transcriptional and transcriptional mechanisms and its loss confers sensitivity to PARP inhibition. Nucleic Acids Res. 2021;49(20):11666-11689.
Bakr A, Oing C, Köcher S, et al. Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Res. 2015;43(6):3154-3166.
Aymard F, Bugler B, Schmidt CK, et al. Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks. Nat Struct Mol Biol. 2014;21(4):366-374.
Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
Bader GD, Hogue CWV. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4(1):2.
Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10(1):26-39.
Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet. 2019;20(11):657-674.
Gan Y, Li X, Han S, et al. The cGAS/STING pathway: a novel target for cancer therapy. Front Immunol. 2021;12:795401.
Shi L, Shi J, Shi X, Li W, Wen H. Histone H3.3 G34 mutations alter histone H3K36 and H3K27 methylation in cis. J Mol Biol. 2018;430(11):1562-1565.
Jain SU, Khazaei S, Marchione DM, et al. Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression. Proc Natl Acad Sci U S A. 2020;117(44):27354-27364.
de Krijger I, van der Torre J, Peuscher MH, Eder M, Jacobs JJL. H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres. Oncogene. 2020;39(25):4814-4827.
Shah MY, Martinez-Garcia E, Phillip JM, et al. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents. Oncogene. 2016;35(45):5905-5915.
Bakr A, Köcher S, Volquardsen J, et al. Functional crosstalk between DNA damage response proteins 53BP1 and BRCA1 regulates double strand break repair choice. Radiother Oncol. 2016;119(2):276-281.
Escribano-Díaz C, Orthwein A, Fradet-Turcotte A, et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell. 2013;49(5):872-883.
Isono M, Niimi A, Oike T, et al. BRCA1 directs the repair pathway to homologous recombination by promoting 53BP1 dephosphorylation. Cell Rep. 2017;18(2):520-532.
Bakr A, Köcher S, Volquardsen J, et al. Impaired 53BP1/RIF1 DSB mediated end-protection stimulates CtIP-dependent end resection and switches the repair to PARP1-dependent end joining in G1. Oncotarget. 2016;7(36):57679-57693.
Yum S, Li M, Chen ZJ. Old dogs, new trick: classic cancer therapies activate cGAS. Cell Res. 2020;30(8):639-648.
Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18(1):152.
Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548(7668):466-470.
Lim J, Park JH, Baude A, et al. The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing. Sci Rep. 2017;7(1):13459.
Rückert M, Flohr AS, Hecht M, Gaipl US. Radiotherapy and the immune system: more than just immune suppression. Stem Cells. 2021;39(9):1155-1165.
Galluzzi L, Aryankalayil MJ, Coleman CN, Formenti SC. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023;20(8):543-557.
Wang Q, Bergholz JS, Ding L, et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat Commun. 2022;13(1):3022.
An X, Zhu Y, Zheng T, et al. An analysis of the expression and association with immune cell infiltration of the cGAS/STING pathway in pan-cancer. Mol Ther Nucleic Acids. 2019;14:80-89.
Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830-842.
Li J, Duran MA, Dhanota N, et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discov. 2021;11(5):1212-1227.
Bakhoum SF, Ngo B, Laughney AM, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553(7689):467-472.

Auteurs

Daniela Mancarella (D)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

Henrik Ellinghaus (H)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Gianluca Sigismondo (G)

Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), and Heidelberg University Medical Faculty, Heidelberg, Germany.

Olivera Veselinov (O)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Alexander Kühn (A)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

Ashish Goyal (A)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Mark Hartmann (M)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Section Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jörg Fellenberg (J)

Department of Experimental Orthopaedics, Orthopaedic University Hospital Heidelberg, Ruprecht Karl University of Heidelberg, Heidelberg, Germany.

Jeroen Krijgsveld (J)

Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), and Heidelberg University Medical Faculty, Heidelberg, Germany.

Christoph Plass (C)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.

Odilia Popanda (O)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Peter Schmezer (P)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Ali Bakr (A)

Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Classifications MeSH